Clinical Pharmacology Knowledge, Opportunities and Working Strengths (CPKNOWS): a competency model for pursuit of excellence in clinical pharmacology
Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects
Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects
Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach
An exploratory microdialysis study investigating the effect of repeated application of a diclofenac epolamine medicated plaster on prostaglandin concentrations in skeletal muscle after standardized physical exercise
Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study
Population pharmacokinetics of recombinant human C1 inhibitor in patients with hereditary angioedema
Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects
Pharmacokinetic–pharmacodynamic studies of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor MK-0916 in healthy subjects
Understanding the dose–response relationship of allopurinol: predicting the optimal dosage
The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis
Dissemination and uptake of a new treatment pathway for paracetamol poisoning in the UK: a survey of healthcare professionals
A novel approach to pharmaco-EEG for investigating analgesics: assessment of spectral indices in single-sweep evoked brain potentials
Not-in-trial simulation I: Bridging cardiovascular risk from clinical trials to real-life conditions
Effects of MHRA drug safety advice on time trends in prescribing volume and indices of clinical toxicity for quinine
Junior doctors’ perceptions of their self-efficacy in prescribing, their prescribing errors and the possible causes of errors
Tacrolimus placental transfer at delivery and neonatal exposure through breast milk
Is the dose of dabigatran really more predictable than warfarin?
Response from John Posner, author of commentary
Antiplatelet and anticoagulation therapy